B
Bull
Bull · 25%DBVT
$5.31
Scenario price
$13.540
-0.818 (-6.04%)At close
Loading chart…
- High
- 14.380
- Open
- 14.380
- VWAP
- 13.79
- Vol
- 146.15K
- Mkt Cap
- 81.60M
- Low
- 13.450
- Amount
- 2.02M
- EV/EBITDA, TTM
- -0.15
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
AI analysis of Dbv Technologies SA (DBVT)
holdDBV Technologies is currently not a strong buy due to its low RSI of 33.968 and a recent price drop of 6.94% over the past five days, indicating bearish momentum. However, the company has a significant cash reserve of $174.9 million, which supports ongoing operations and R&D, and analysts maintain a positive outlook with targets as high as $55, suggesting potential upside. The main risk is the company's negative earnings per share of -$0.12 reported in Q2, which reflects ongoing profitability challenges.
Analyst Ratings (9)
+242.69% upside
Buy
8 Buy
1 Hold
0 Sell
Current: 13.54
Low
40.00
Average
46.40
High
51.00
H.C. Wainwright
Buy
$40
2026-06-30
H.C. Wainwright
2026-06-30
Price Target
$40
Buy
Cantor Fitzgerald
Overweight
$48
2026-06-30
Cantor Fitzgerald
2026-06-30
Price Target
$48
Overweight
Citizens
Outperform
$55
2026-06-30
Citizens
2026-06-30
Price Target
$55
Outperform
Citizens
Outperform
$55
2026-05-01
Citizens
2026-05-01
Price Target
$55
Outperform
Goldman Sachs
Sell
—
2026-04-09
Goldman Sachs
2026-04-09
Price Target
—
Sell
Valuation Metrics
The current forward P/E ratio for Dbv Technologies SA (DBVT) is 0.00, compared to its 5-year average forward P/E of -3.83.
Alphio AI Price Scenarios for DBVT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding DBVT
Events Timeline
News
8.507-30GlobenewswireDBV Technologies Sells $50 Million ADSs via ATM Program
8.507-17NewsfilterDBV Technologies Files ATM Prospectus for Up to $150 Million
9.507-16seekingalphaDBV Technologies Q2 Earnings Beat Expectations
- 9.507-14Newsfilter
DBV Technologies to Report Q2 2026 Financial Results on July 16
- 8.507-06Newsfilter
DBV Technologies Half-Year Report on Liquidity Contract with ODDO BHF
DBVT FAQ — answered by Alphio AI
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
DBV Technologies is currently not a strong buy due to its low RSI of 33.968 and a recent price drop of 6.94% over the past five days, indicating bearish momentum. However, the company has a significant cash reserve of $174.9 million, which supports ongoing operations and R&D, and analysts maintain a positive outlook with targets as high as $55, suggesting potential upside. The main risk is the company's negative earnings per share of -$0.12 reported in Q2, which reflects ongoing profitability challenges.
9 analysts cover DBVT: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 46.40.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.